2025 SPS Puerto Rico | Infliximab Intravenous vs. Subcutaneous: Clinical and Practice Considerations
Overview
Bhavesh Shah focused on infusion center challenges, notably staffing shortages that cost Boston Medical Center $20 million annually and strain patient access and nurse-to-patient ratios. To address rising infliximab use and labor demands, Sub Q therapies were proposed to enhance efficiency and reduce costs. Presented at 2025 SPS Puerto Rico.
Target Audience
Pharmacists
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Bhavesh Shah, RPh, BCOP
Date of Release
June 13th, 2025
-%20Less%20is%20More-1749834394770.webp&w=3840&q=75)